Moreover, SOX17 low expression has been shown to associate with cisplatin or radiation resistance in colorectal cancer, endometrial cancer, or rat mammary carcinoma [36–38], suggesting the pivotal role(s) of SOX17 down-regulation in therapy-resistant cancers. This evidence concerns the gene SOX17 and breast carcinoma.